QINGDAO - AstraZeneca, the global pharmaceutical giant, announced an investment in manufacturing -- a big plant in Qingdao last year, and AstraZeneca announced the company will invest 2.5 billion U.S. dollars in a research and development center in Beijing on Mar 24.  

The investment is focused on accelerating scientific innovation, leveraging artificial intelligence (AI) in drug development, aimed at enhancing AstraZeneca's research and development capabilities to address both local and global healthcare needs.

AI is a cornerstone of AstraZeneca's drug development strategy, and Soriot emphasized the transformative impact the technology has on the industry.
Beyond innovation, AstraZeneca is prioritizing patient care through early diagnosis and chronic disease management.